State-of-the-Art PaperAge as a Risk Factor for Stroke in Atrial Fibrillation Patients: Implications for Thromboprophylaxis
Under an Elsevier user license
open archive
Key Words
atrial fibrillation
bleeding risk
elderly
net clinical benefit
stroke risk
warfarin
Abbreviations and Acronyms
AF
atrial fibrillation
CI
confidence interval
HR
hazard ratio
ICH
intracranial hemorrhage
INR
international normalized ratio
OAC
oral anticoagulation
RCT
randomized controlled trial
RR
relative risk
TIA
transient ischemic attack
TTR
time in therapeutic range
Cited by (0)
Prof. Lip has served as a consultant for Bayer, Astellas, Merck, AstraZeneca, Sanofi, Aryx, Portola, Biotronic, and Boehringer, and has been on the Speakers' Bureau for Bayer, Boehringer, and Sanofi. Dr. Lane is in receipt of an investigator-initiated educational grant from Bayer Healthcare, and has received industry-funded sponsorship for travel to cardiology conferences. All other authors have reported that they do not have any relationships to disclose.
Copyright © 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.